ConvaTec (GB:CTEC)
LSE:CTEC
Want to see GB:CTEC full AI Analyst Report?
CTEC Stock Chart & Stats
230.00 p
1.06 p(0.47%)
At close: 4:00 PM EST
230.00 p
1.06 p(0.47%)
Day’s Range― - ―
52-Week Range195.50 p - 311.20 p
Previous CloseN/A
Volume85.46K
Average Volume (3M)6.27M
Market Cap
£3.94B
Enterprise Value6.84B
Total Cash (Recent Filing)£75.03M
Total Debt (Recent Filing)£1.61B
Price to Earnings (P/E)30.3
Beta1.05
Next Earnings
Aug 04, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield2.11%
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,954,852,000
10 Day Avg. Volume5,278,857
30 Day Avg. Volume6,266,139
Financial Highlights & Ratios
PEG Ratio-7.34
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£305.40Price Target Upside32.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.2
Revenue Forecast (FY)£2.57B
Bulls Say, Bears Say
Bulls Say
Consistent Organic GrowthFive years of >5% organic growth (6.4% in 2025 ex‑InnovaMatrix) and guidance for 5–7% in 2026 with a 6–8% medium‑term target indicate durable demand for consumable chronic‑care products. The recurring consumables model and broad pipeline support sustained revenue expansion over multiple years.
Operating Margin ExpansionMaterial margin improvement to 22.3% in 2025 (110bps increase) and management targets of ≥23% next year and mid‑20s long‑term reflect structural gains from pricing, productivity and simplification. Sustained operating leverage enhances cash flow resilience and funds reinvestment without relying solely on external capital.
Strong Free Cash Flow & Capital AllocationRobust FCF generation ($362m, ~101% conversion) and active capital returns (H2 2025 $300m buyback and dividend growth) demonstrate strong cash conversion. This supports growth CapEx, funds capacity expansion and returns capital to shareholders while preserving flexibility to invest in the pipeline over the medium term.
Bears Say
Higher Financial LeverageLeverage increased materially (debt/equity ~1.06 in 2025) with management managing net debt/EBITDA around 2x. Elevated debt reduces financial flexibility, increases interest‑rate and refinancing risk, and constrains ability to fund opportunistic M&A or absorb shocks without pressuring cash returns or investment plans.
Regulatory Quality-System Risk (FDA)An FDA warning letter for complaints/CAPA deficiencies points to systemic quality‑management gaps. Remediation can be costly and time consuming, may delay or restrict new product launches, invite heightened inspections and create procurement or reputational impacts that could impair durable revenue growth if unresolved.
Reimbursement Vulnerability (InnovaMatrix)An ~80% CMS price reduction for InnovaMatrix triggered steep sales declines, a $72m impairment and ongoing channel/legal uncertainty. This underscores exposure to reimbursement policy shifts and channel disruption for acquired products, which can permanently alter product economics and create lasting revenue headwinds.
ConvaTec News
CTEC FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest share price was 195.50 p and its highest was 311.20 p in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is £3.94B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 65 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported 0.072 p earnings per share for the quarter, missing the consensus estimate of 0.075 p by -0.002 p.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of 1.399 p which represents an annual dividend yield of 2.11%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.06.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of 0.072 p in its last earnings report, missing expectations of 0.075 p. Following the earnings report the stock price went up 10.397%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in GB:CTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£305.40 (32.78% Upside)
£305.40 (32.78% Upside)
Insider Transactions
Sold Shares
Worth £596.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
10.53%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
CTEC Stock 12 Month Forecast
Average Price Target
305.40 p
▲(32.78% Upside)
Technical Analysis
Options Prices
Currently, No data available
---